[go: up one dir, main page]

EA201290135A1 - Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин - Google Patents

Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин

Info

Publication number
EA201290135A1
EA201290135A1 EA201290135A EA201290135A EA201290135A1 EA 201290135 A1 EA201290135 A1 EA 201290135A1 EA 201290135 A EA201290135 A EA 201290135A EA 201290135 A EA201290135 A EA 201290135A EA 201290135 A1 EA201290135 A1 EA 201290135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
epo
recombinant human
erythropoiethin
erythropoietine
erythropoetin
Prior art date
Application number
EA201290135A
Other languages
English (en)
Other versions
EA022396B1 (ru
Inventor
Вальтер Хиндерер
Штефан Арнольд
Original Assignee
Байодженерикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байодженерикс Аг filed Critical Байодженерикс Аг
Publication of EA201290135A1 publication Critical patent/EA201290135A1/ru
Publication of EA022396B1 publication Critical patent/EA022396B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предложен способ получения эритропоэтина (ЕРО), в частности рекомбинантного эритропоэтина человека (rhEPO), с определенным составом гликоформ и с высокой степенью чистоты, т.е. с высоким содержанием О-гликозилированных изоформ ЕРО.
EA201290135A 2009-09-23 2010-09-23 Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин EA022396B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09012120 2009-09-23
PCT/EP2010/005839 WO2011035914A1 (en) 2009-09-23 2010-09-23 Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same

Publications (2)

Publication Number Publication Date
EA201290135A1 true EA201290135A1 (ru) 2012-10-30
EA022396B1 EA022396B1 (ru) 2015-12-30

Family

ID=41566362

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290135A EA022396B1 (ru) 2009-09-23 2010-09-23 Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин

Country Status (14)

Country Link
US (1) US20120264688A1 (ru)
EP (1) EP2480569B1 (ru)
JP (1) JP5728016B2 (ru)
KR (1) KR20120117728A (ru)
CN (1) CN102712688B (ru)
AU (1) AU2010297530B2 (ru)
BR (1) BR112012006602A2 (ru)
CA (1) CA2775012A1 (ru)
EA (1) EA022396B1 (ru)
IL (1) IL218721A0 (ru)
MX (1) MX2012003558A (ru)
UA (1) UA107678C2 (ru)
WO (1) WO2011035914A1 (ru)
ZA (1) ZA201202491B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
EP2970420A4 (en) * 2013-03-15 2016-08-17 Apotex Inc STABILITY OF THE ENHANCED LIQUID FORMULATION OF ERYTHROPOIETIN ALPHA VIA A PURIFICATION TREATMENT
WO2014204023A1 (ko) * 2013-06-17 2014-12-24 씨제이헬스케어 주식회사 신규한 다베포에틴 알파의 정제 방법
WO2015010030A1 (en) * 2013-07-18 2015-01-22 Children's Hospital Medical Center Methods of improving titer in transfection-based production systems using eukaryotic cells
WO2015134640A1 (en) * 2014-03-05 2015-09-11 GlycoScientific LLC Isotopically labeled glycans and methods for producing the same
JP6906497B2 (ja) * 2016-03-09 2021-07-21 Ｊｃｒファーマ株式会社 変異型ヒトエリスロポエチンの製造方法
WO2017169978A1 (ja) * 2016-03-31 2017-10-05 株式会社カネカ 精製されたネコ由来エリスロポエチンの製造方法
US12022847B2 (en) 2017-06-26 2024-07-02 Michael Foods, Inc. Methods of egg yolk fractionation
EP3613486B1 (de) * 2018-08-24 2020-10-07 UGA Biopharma GmbH Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat
CN115015415A (zh) * 2022-05-30 2022-09-06 科兴生物制药股份有限公司 重组人促红细胞生成素的含量检测方法
CN119371491A (zh) * 2024-12-25 2025-01-28 杭州诺泰诺和生物医药科技有限公司 Pegcetacoplan的纯化方法和制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
IL79176A (en) 1985-06-20 1992-06-21 Kirin Amgen Inc Process for the recovery of erythropoietin from a fluid
EP0248656B1 (en) 1986-06-04 1993-03-31 Director-General of the Agency of Industrial Science and Technology Composition for cell cultivation and use thereof
DE3787805T2 (de) 1986-08-04 1994-02-10 Garvan Inst Med Res Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0343635B1 (en) 1988-05-25 1994-08-24 Teijin Limited Process for continuously culturing adherent animal cells
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
EP1484412A3 (en) 1989-12-22 2007-10-17 Laboratoires Serono SA Eukaryotic host cell line in which an endogenous gene has been activated, and uses thereof
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE4115722A1 (de) 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
TR200001580T2 (tr) * 1997-12-03 2000-12-21 Roche Diagnostics Gmbh Spesifik etkinliği yüksek eritropoyetin
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AU784091B2 (en) * 2000-05-15 2006-02-02 F. Hoffmann-La Roche Ag New pharmaceutical composition
US20020045192A1 (en) * 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
US6930086B2 (en) * 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
EP1453857B1 (en) 2001-11-28 2014-08-13 Sandoz AG Chromatographic purification of recombinant human erythropoietin
DE60220451T2 (de) 2002-03-26 2008-01-24 Lek Pharmaceutical And Chemical Co. D.D. Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
ATE405644T1 (de) 2002-12-13 2008-09-15 Bioceuticals Arzneimittel Ag Verfahren zur herstellung und reinigung von erythropoietin
EP1537876A1 (en) 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1844068A4 (en) * 2005-01-25 2009-09-30 Apollo Life Sciences Ltd MOLECULES AND THEIR CHIMERIC MOLECULES
WO2008057161A1 (en) * 2006-11-09 2008-05-15 Synageva Biopharma Corp Avian derived erythropoietin
US20090105462A1 (en) * 2006-11-09 2009-04-23 Ivarie Robert D Glycosylated erythropoietin
JP5694171B2 (ja) * 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用

Also Published As

Publication number Publication date
EP2480569B1 (en) 2016-04-13
CN102712688A (zh) 2012-10-03
KR20120117728A (ko) 2012-10-24
JP2013505276A (ja) 2013-02-14
US20120264688A1 (en) 2012-10-18
MX2012003558A (es) 2012-07-03
ZA201202491B (en) 2012-12-27
EP2480569A1 (en) 2012-08-01
JP5728016B2 (ja) 2015-06-03
WO2011035914A1 (en) 2011-03-31
EA022396B1 (ru) 2015-12-30
IL218721A0 (en) 2012-06-28
CA2775012A1 (en) 2011-03-31
AU2010297530B2 (en) 2013-12-19
CN102712688B (zh) 2015-06-24
BR112012006602A2 (pt) 2019-09-24
UA107678C2 (ru) 2015-02-10
AU2010297530A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
EA201290135A1 (ru) Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
PH12014502766A1 (en) Fibroblast growth factor 21 proteins
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
BR112013010522A2 (pt) método para purificação de fator estimulador de colônias de granulócitos humano a partir recombinantes de e. coli
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
UA113856C2 (xx) Злитий білок для лікування порушень метаболізму
EA201290295A1 (ru) Специфичные к рецептору меланокортина-1 линейные пептиды
ATE491794T1 (de) Zusammensetzung und verfahren zur herstellung von steviolglykosiden
SG10201806648TA (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
MA33976B1 (fr) Spiroindolinone pyrrolidines
IN2014CN03937A (ru)
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
MX2014015258A (es) Variantes del factor 21 de crecimiento de fibroblasto.
NO20076672L (no) Produksjon av rekombinant IL-18 bindingsprotein
ATE548382T1 (de) Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
MX2013001447A (es) Metodo de produccion y purificacion de una sialiltransferasa soluble activa.
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
NO20080580L (no) Serumfritt kulturmedium for produksjon av redkombinante gonadotropiner
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU